Fed’s Powell opens door to potential rate cuts at Jackson Hole
Anthony J. Recupero, the President of Commercial Operations at SI-BONE, Inc. (NASDAQ:SIBN), a medical device company with a robust gross profit margin of 79% and revenue of $167 million in the last twelve months, has recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 7.66. The transactions, which occurred on April 2, totaled $46,852. The sales included two separate transactions, with shares sold at weighted average prices ranging from $14.1279 to $14.1707.
The stock sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as detailed in the filing. Following these transactions, Recupero holds 284,555 shares directly, which includes 171,070 shares issuable upon the settlement of restricted stock units. With analyst price targets ranging from $19 to $32, investors seeking deeper insights into SI-BONE’s valuation and growth prospects can access comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, SI-BONE Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $49 million, which surpassed analyst projections and marked a 26% year-over-year increase. The company’s earnings per share (EPS) also exceeded expectations, coming in at -$0.11 compared to the forecast of -$0.15. SI-BONE’s strong performance was driven by a 28% revenue growth in the U.S. market and a significant increase in the number of active surgeons utilizing its products. Looking forward, SI-BONE has set its 2025 revenue guidance to range between $193.5 million and $195.5 million, indicating expected growth of 16% to 17%.
Additionally, SI-BONE achieved positive adjusted EBITDA of $1.9 million in the fourth quarter, a milestone that highlights the company’s improving financial management. Analyst firms such as Cantor Fitzgerald and Needham have shown confidence in SI-BONE’s future prospects, with Cantor Fitzgerald maintaining an Overweight rating and Needham raising its stock price target to $24. The firms noted the company’s strong guidance and potential for revenue guidance to exceed expectations. SI-BONE’s strategic focus on innovation and its expanding product portfolio continue to receive favorable responses from the medical community, enhancing its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.